Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
This acknowledgement represents the third of several oral suspensions in neuroscience that OWP Pharmaceuticals hopes to commercialize over the next several years via a 505(b)(2) application.